Sementis Ltd is developing a novel vaccine platform designed to deliver new vaccines and immunotherapies to the world’s most challenging and complex diseases by unlocking the potential of vaccinia as a recombinant viral vector.

The COVID-19 pandemic revealed the need for established vaccine ready platforms that can be rapidly developed and scaled in the event of new emerging disease.

Sementis has built on the established safety and efficacy of vaccinia-based vaccines and ~10-year experience to deliver the novel Sementis Copenhagen Vector (SCV) viral vector vaccine platform. Designed to deliver new vaccines and immunotherapies to the world’s most challenging and complex diseases – rapidly and to scale.

• Builds on the established safe and efficacious profile of vaccinia vaccines and addresses the issues of manufacturing scale and speed.

• Demonstrated utility and versatility of the platform as a combination vaccine, to express multiple and unstable immunogens.

• Platform technology being positioned for rapid response to emerging threats.

• Evidence of broad and potent T-cell immunity, and long-lasting protective vaccine immune response.

• Patent protected core technology.

Proof-of-concept has been completed, a global team of experts in contemporary vaccine development built and plan ready to accelerate into clinical development.